Lonza Group Ag (OTCMKTS:LZAGY) Sees Large Decrease in Short Interest

Lonza Group Ag (OTCMKTS:LZAGY) was the recipient of a significant decrease in short interest in May. As of May 29th, there was short interest totaling 27,683 shares, a decrease of 50.0% from the May 14th total of 55,395 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 135,751 shares, the short-interest ratio is currently 0.2 days.

Analyst Ratings Changes

Separately, Zacks Research raised Lonza Group from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Lonza Group presently has a consensus rating of “Moderate Buy”.

Lonza Group Stock Performance

LZAGY stock opened at $61.53 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.24 and a quick ratio of 1.77. The company’s 50-day moving average price is $63.17 and its 200 day moving average price is $65.52. Lonza Group has a 52 week low of $58.53 and a 52 week high of $73.85.

About Lonza Group

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.